What changed 10-K

Item 2. Properties

2022-03-28 compared with 2021-03-31 · 7 added, 6 removed, 2 unchanged (87% of the section changed)

1 unchanged sentence

lease a 14,507 square foot manufacturing facility in Irvine, California.

We renewed our lease on September 20, 2017, effective

October 1, 2017, for five years with an option to extend the lease for an additional 60-month term at the end of lease term.

facility is designed expressly for the manufacture of biologic vascular grafts and is equipped for research and development,

prototype fabrication, cGMP manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices.

We believe that our facilities are sufficient for the near future as there is present capacity to manufacture up to 24,000 venous

valves per year to meet potential market demands.

We amended our lease on November 17, 2021 to extend the term

an additional 60 months from its September 30, 2022 expiration date to a new expiration date of September 30, 2027.

Our facility is designed

expressly for the manufacture of biologic vascular grafts and is equipped for research and development, prototype fabrication, cGMP manufacturing

and shipping for Class III medical devices, including biologic cardiovascular devices.

We believe that our facilities are sufficient

for the near future as there is present capacity to manufacture up to approximately 24,000 venous valves per year to meet potential market

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.